Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP2 | O95551 | 6/20 | 0.67 |
| ▸ | PGR | P06401 | 1/20 | 0.58 |
| ▸ | AHR | P35869 | 3/20 | 0.54 |
| ▸ | CMA1 | P23946 | 2/20 | 0.54 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.53 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.48 |
| ▸ | CDK1 | P06493 | 2/20 | 0.48 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.48 |
| ▸ | GSK3B | P49841 | 2/20 | 0.48 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.48 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.48 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.48 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CDC7 | O00311 | 1/20 | 0.47 |
| ▸ | PLK4 | O00444 | 1/20 | 0.47 |
| ▸ | IKBKB | O14920 | 1/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19954 | 0.86 | PGR (0.71) | TDP2PGRAHRCCNB2CDK1 | |
| SCHEMBL30270534 | 0.85 | CA9 (0.56) | TDP2PGRCAPN9CASP3CYP3A4 | |
| SCHEMBL495833 | 0.85 | CA9 (0.56) | TDP2PGRCAPN9CASP3CYP3A4 | |
| SCHEMBL2616914 | 0.84 | TDP2 (0.73) | TDP2PGRCAPN9CASP3CYP3A4 | |
| SCHEMBL13982356 | 0.83 | AHR (0.54) | TDP2PGRAHRCMA1EIF2AK2 | |
| SCHEMBL2061055 | 0.82 | MAPT (0.51) | TDP2PGRCAPN9CASP3CYP3A4 | |
| Oxindole SCHEMBL27763978 | 0.81 | AHR (0.70) | TDP2PGRAHRCCNB2CDK1 | |
| SCHEMBL3563285 | 0.80 | TDP2 (1.00) | TDP2PGRCASP3CYP3A4TDP1 | |
| SCHEMBL1122774 | 0.80 | TDP2 (0.82) | TDP2PGRCAPN9CASP3CYP3A4 | |
| SCHEMBL3483943 | 0.79 | EIF2AK2 (0.57) | TDP2PGRAHRCMA1EIF2AK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160060260-A1 | BROMODOMAIN INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-03-03 | — | — | US | disclosed |
| US-20120270859-A1 | INDOLINE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-25 | — | — | US | disclosed |
| US-8207179-B2 | Substituted indolines as tyrosine kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-8207179-B2 | Substituted indolines as tyrosine kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-8207179-B2 | Substituted indolines as tyrosine kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-20100222331-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
| US-20100222331-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
| US-7763263-B2 | Skin external agents and drugs | KAO CORPORATION (JP) | 2010-07-27 | — | — | US | disclosed |
| US-20100184747-A1 | INDOLINE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-22 | — | — | US | disclosed |
| EP-2181108-A2 | 3-HETROCYCLYLIDENE-INDOLINONE DERIVATIVES AS INHIBITORS OF SPECIFIC CELL CYCLE KINASES | Boehringer Ingelheim International GmbH (DE) | 2010-05-05 | — | — | EP | disclosed |
| US-20080132540-A1 | NON-PEPTIDIC NPY Y2 RECEPTOR INHIBITORS | CARRUTHERS NICHOLAS I | 2008-06-05 | — | — | US | disclosed |
| US-7317025-B2 | Non-peptidic NPY Y2 receptor inhibitors | JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, LLC (US) | 2008-01-08 | — | — | US | disclosed |
| US-20060177408-A1 | Skin external agents and drugs | KANEBO COSTMETICS INC. | 2006-08-10 | — | — | US | disclosed |
| WO-2005030754-A1 | INDOLE OR QUINOLINE DERIVATIVES AS NON-PEPTICID NPY Y2 RECEPTOR INHIBITORS USEFUL FOR THE TREATMENT OF ANXIOLYTIC AND DEPRESSIVE DISORDERS AND OBESITY | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-04-07 | — | — | WO | disclosed |
| US-20050070534-A1 | Non-peptidic NPY Y2 receptor inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-03-31 | — | — | US | disclosed |
| US-20040254185-A1 | Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3 | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-12-16 | — | — | US | disclosed |
| EP-1392680-A2 | SELECTIVE ANTHRANILAMIDE PYRIDINE AMIDES AS INHIBITORS OF VEGFR-2 AND VEGFR-3 | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002090352-A2 | SELECTIVE ANTHRANILAMIDE PYRIDINE AMIDES AS INHIBITORS OF VEGFR-2 AND VEGFR-3 | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-11-14 | — | — | WO | disclosed |
| CN-1319090-A | Novel substuted indolimones, their preparation process and use as medicine | BOEHRINGER INGELHEIM PHARMA (DE) | 2001-10-24 | — | — | CN | disclosed |
| CN-86105309-A | Oxindole-3-carbonyl amines the compound that replaces as the 1-of anti-inflammatory and anodyne | — | 1987-01-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270859-A1 | INDOLINE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | IDO1, INMT, TPH1 | TDP2 1567/4885PGR 165/4885AHR 61/4885 |
| US-20060177408-A1 | Skin external agents and drugs | CUTA, F12, NFE2 | TDP2 2850/4885PGR 3288/4885AHR 4325/4885 |
| US-20160060260-A1 | BROMODOMAIN INHIBITORS FOR TREATING DISEASE | BRDT, BRPF3, BRWD1 | TDP2 1348/4885PGR 2682/4885AHR 3759/4885 |
| US-20080132540-A1 | NON-PEPTIDIC NPY Y2 RECEPTOR INHIBITORS | NPY2R, NPY1R, NPY5R | TDP2 1201/4885PGR 209/4885AHR 3065/4885 |
| US-20040254185-A1 | Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3 | FLT4, KDR, FLT1 | TDP2 2581/4885PGR 293/4885AHR 80/4885 |
| US-20100184747-A1 | INDOLINE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | IDO1, INMT, TPH1 | TDP2 1567/4885PGR 165/4885AHR 61/4885 |
| US-20100222331-A1 | NEW COMPOUNDS | CCNA1, CCNY, MKI67 | TDP2 3448/4885PGR 390/4885AHR 2025/4885 |
| US-20050070534-A1 | Non-peptidic NPY Y2 receptor inhibitors | NPY2R, NPY1R, NPY5R | TDP2 1201/4885PGR 209/4885AHR 3065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.